Page last updated: 2024-12-08
lilly 18947
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Lilly 18947: RN given refers to parent cpd; Lilly 18947 refers to HBr salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 164997 |
SCHEMBL ID | 2065922 |
MeSH ID | M0042586 |
Synonyms (21)
Synonym |
---|
2,4-dichloro-6-phenylphenoxyethyldiethylamine hydrobromide |
lilly 18947 hydrobromide |
ethanamine, 2-((3,5-dichloro(1,1'-biphenyl)-2-yl)oxy)-n,n-diethyl-, hydrobromide |
triethylamine, 2-((3,5-dichloro-2-biphenylyl)oxy)-, hydrobromide |
lilly 18947 |
n,n-diethyl-2-(2,4-dichloro-6-phenylphenoxy)ethylamine |
5957-22-2 |
2-(2,4-dichloro-6-phenylphenoxy)-n,n-diethylethanamine |
ly 18947 (for hydrobromide) |
n-((2,4-dichloro-6-phenylphenoxy)ethyl)-n,n-diethylamine |
triethylamine, 2-(3,5-dichloro-2-biphenylyl)oxy)- |
2,4-dichloro-6-phenylphenoxyethyldiethylamine |
ethanamine, 2-((3,5-dichloro(1,1'-biphenyl)-2-yl)oxy)-n,n-diethyl- |
((2,4-dichloro-6-phenylphenoxy)ethyl)diethylamine |
2600-77-3 |
SCHEMBL2065922 |
2-((3,5-dichloro-[1,1'-biphenyl]-2-yl)oxy)-n,n-diethylethan-1-amine |
DTXSID50948903 |
2-[(3,5-dichloro[1,1'-biphenyl]-2-yl)oxy]-n,n-diethylethan-1-amine |
ethanamine, 2-[(3,5-dichloro[1,1'-biphenyl]-2-yl)oxy]-n,n-diethyl- |
AKOS040747091 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (75.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.34
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |